CN103751225A - 蛹虫草抗肿瘤活性组分的提取方法及其应用 - Google Patents
蛹虫草抗肿瘤活性组分的提取方法及其应用 Download PDFInfo
- Publication number
- CN103751225A CN103751225A CN201410041855.9A CN201410041855A CN103751225A CN 103751225 A CN103751225 A CN 103751225A CN 201410041855 A CN201410041855 A CN 201410041855A CN 103751225 A CN103751225 A CN 103751225A
- Authority
- CN
- China
- Prior art keywords
- component
- cordyceps militaris
- antitumor
- link
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 72
- 241001264174 Cordyceps militaris Species 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 title claims abstract description 38
- 239000004480 active ingredient Substances 0.000 title abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 30
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 claims abstract description 20
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000010828 elution Methods 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 12
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 10
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 10
- 238000000227 grinding Methods 0.000 claims abstract description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 20
- 239000012043 crude product Substances 0.000 claims description 20
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 19
- 238000001556 precipitation Methods 0.000 claims description 18
- 238000012360 testing method Methods 0.000 claims description 18
- 238000010829 isocratic elution Methods 0.000 claims description 17
- 238000004262 preparative liquid chromatography Methods 0.000 claims description 16
- 238000000926 separation method Methods 0.000 claims description 16
- 201000005202 lung cancer Diseases 0.000 claims description 15
- 208000020816 lung neoplasm Diseases 0.000 claims description 15
- 238000000338 in vitro Methods 0.000 claims description 14
- 238000012216 screening Methods 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 10
- 230000010261 cell growth Effects 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 7
- 238000002390 rotary evaporation Methods 0.000 claims description 7
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 7
- 239000012498 ultrapure water Substances 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- 238000000638 solvent extraction Methods 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 238000007445 Chromatographic isolation Methods 0.000 claims description 3
- 239000002826 coolant Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 14
- 239000002244 precipitate Substances 0.000 abstract description 3
- 238000003811 acetone extraction Methods 0.000 abstract description 2
- 238000004811 liquid chromatography Methods 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 description 55
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 38
- 241000699670 Mus sp. Species 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 34
- 239000003814 drug Substances 0.000 description 34
- 229960004397 cyclophosphamide Drugs 0.000 description 21
- 239000000463 material Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- 230000037396 body weight Effects 0.000 description 14
- 238000000605 extraction Methods 0.000 description 13
- 235000005911 diet Nutrition 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000000378 dietary effect Effects 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 9
- 229920000053 polysorbate 80 Polymers 0.000 description 9
- 241000190633 Cordyceps Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000003809 water extraction Methods 0.000 description 8
- 238000003304 gavage Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000233866 Fungi Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000004570 mortar (masonry) Substances 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 208000037063 Thinness Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000001644 anti-hepatocarcinoma Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000000249 desinfective effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000000247 postprecipitation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 206010048828 underweight Diseases 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 241000707825 Argyrosomus regius Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 241000130660 Hepialidae Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000004332 phalangeal cell Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410041855.9A CN103751225B (zh) | 2014-01-27 | 2014-01-27 | 蛹虫草抗肿瘤活性组分的提取方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410041855.9A CN103751225B (zh) | 2014-01-27 | 2014-01-27 | 蛹虫草抗肿瘤活性组分的提取方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103751225A true CN103751225A (zh) | 2014-04-30 |
CN103751225B CN103751225B (zh) | 2016-01-20 |
Family
ID=50518652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410041855.9A Expired - Fee Related CN103751225B (zh) | 2014-01-27 | 2014-01-27 | 蛹虫草抗肿瘤活性组分的提取方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103751225B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105380994A (zh) * | 2015-12-09 | 2016-03-09 | 正源堂(天津)生物科技有限公司 | 马钱子抗肿瘤活性组分的提取方法及其应用 |
TWI612963B (zh) * | 2016-07-20 | 2018-02-01 | 錢佑 | 具抗發炎與抑制肝癌細胞生長的蛹蟲草萃取物及其製備方法 |
CN111329871A (zh) * | 2020-03-13 | 2020-06-26 | 贵州贵安精准医学研究院股份有限公司 | 蛹虫草预防和治疗肝癌的产品制备方法及应用 |
CN111393497A (zh) * | 2020-03-13 | 2020-07-10 | 贵州贵安精准医学研究院股份有限公司 | 一种预防和治疗肺癌的天然产品制备方法及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101613390A (zh) * | 2009-07-21 | 2009-12-30 | 贵州大学 | 一种高纯度虫草菌素分离纯化的方法 |
CN102977172A (zh) * | 2011-10-26 | 2013-03-20 | 中国科学院沈阳应用生态研究所 | 一种提取虫草素的方法 |
CN103520222A (zh) * | 2012-07-02 | 2014-01-22 | 上海国宝企业发展中心 | 北冬虫夏草提取物及其在制备治疗肿瘤药物上的应用 |
-
2014
- 2014-01-27 CN CN201410041855.9A patent/CN103751225B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101613390A (zh) * | 2009-07-21 | 2009-12-30 | 贵州大学 | 一种高纯度虫草菌素分离纯化的方法 |
CN102977172A (zh) * | 2011-10-26 | 2013-03-20 | 中国科学院沈阳应用生态研究所 | 一种提取虫草素的方法 |
CN103520222A (zh) * | 2012-07-02 | 2014-01-22 | 上海国宝企业发展中心 | 北冬虫夏草提取物及其在制备治疗肿瘤药物上的应用 |
Non-Patent Citations (1)
Title |
---|
陈伟 等: "反相高效液相色谱法分离和制备虫草素的方法研究", 《上海农业学报》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105380994A (zh) * | 2015-12-09 | 2016-03-09 | 正源堂(天津)生物科技有限公司 | 马钱子抗肿瘤活性组分的提取方法及其应用 |
TWI612963B (zh) * | 2016-07-20 | 2018-02-01 | 錢佑 | 具抗發炎與抑制肝癌細胞生長的蛹蟲草萃取物及其製備方法 |
CN111329871A (zh) * | 2020-03-13 | 2020-06-26 | 贵州贵安精准医学研究院股份有限公司 | 蛹虫草预防和治疗肝癌的产品制备方法及应用 |
CN111393497A (zh) * | 2020-03-13 | 2020-07-10 | 贵州贵安精准医学研究院股份有限公司 | 一种预防和治疗肺癌的天然产品制备方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103751225B (zh) | 2016-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104825500B (zh) | 白肉灵芝提取物、提取方法及其用途 | |
CN103751225B (zh) | 蛹虫草抗肿瘤活性组分的提取方法及其应用 | |
CN102068486A (zh) | 鹰嘴豆豆芽有效部位及其制备方法和应用 | |
JP6389958B2 (ja) | 瓦草5環性トリテルペンサポニン類化合物抗腫瘍の薬物用途 | |
CN102872015B (zh) | 一种白药子总生物碱提取物及其制备方法及应用 | |
CN104027362B (zh) | 用于治疗肺癌的牛樟芝萃取物及其制备方法 | |
US20050287230A1 (en) | Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof | |
CN101028322B (zh) | 毛裂蜂斗菜提取物用于制备防治肿瘤疾病药物的用途 | |
CN103784481B (zh) | 一种从蛹虫草中提取抗肿瘤活性组分的方法及其应用 | |
CN102908340B (zh) | 一种含异甘草黄酮醇的抗肿瘤药物及其应用 | |
CN101396373B (zh) | 一种华蟾素提取物及其制备方法 | |
CN1919339B (zh) | 含有蛋白的葫芦素纳米制剂及制备方法和用途 | |
CN109602759A (zh) | 罗汉松实多糖的用途 | |
CN107365284A (zh) | 一种从红豆杉中提取紫杉醇的方法 | |
CN109929006B (zh) | 阿魏菇中麦角甾醇过氧化物的提取方法及应用 | |
CN111329871A (zh) | 蛹虫草预防和治疗肝癌的产品制备方法及应用 | |
CN102961443B (zh) | 北豆根抗肿瘤提取物、制备方法及用途 | |
CN103751224B (zh) | 从蛹虫草中提取抗肿瘤活性组分的方法及其应用 | |
CN101711790A (zh) | 一种用于治疗肝癌的野生核桃楸树皮水提取物 | |
CN100427099C (zh) | 能够有效治疗脑癌的胡桃楸多糖制剂及其制备方法 | |
CN111393497A (zh) | 一种预防和治疗肺癌的天然产品制备方法及应用 | |
CN103027931B (zh) | 一种海南大风子抗肿瘤有效组分提取物及其制法和用途 | |
CN102028698A (zh) | 一种治疗结肠癌的药物及其制备方法 | |
CN103948746B (zh) | 瑞香狼毒在制备抗肿瘤转移药物中的应用 | |
CN106606616B (zh) | 独角莲抗肿瘤活性部位及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Yaozhou Inventor after: Chen Yujiao Inventor after: Cui Jinsong Inventor after: Shu Tejun Inventor after: Chen Jianqing Inventor before: Zhang Yaozhou Inventor before: Chen Yujiao Inventor before: Cui Jinsong Inventor before: Shu Tejun Inventor before: Chen Jianqing |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150918 Address after: 300457, Tianjin economic and Technological Development Zone, No. 19 West Ring Road, TEDA Service Outsourcing Industrial Park, building 4, room 4302, room three Applicant after: TUKE (TIANJIN) PHARMACEUTICAL TECHNOLOGY CO.,LTD. Address before: 300457 Tianjin international economic and Technological Development Zone, Binhai New Area, Tianjin Dongting Road, No. 220, Tianjin international joint Academy of biological medicine experimental building N511 Applicant before: ZHENGYUANTANG (TIANJIN) BIOTECHNOLOGY CO.,LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170412 Address after: 550025 Guizhou Province in the New District of Guizhou security comprehensive security zone Patentee after: ACADEMY OF PRECISION MEDICINE, GUIAN, GUIZHOU CO.,LTD. Address before: 300457 Tianjin economic and Technological Development Zone, West Ring Road, No. 19 TEDA Service Outsourcing Industrial Park, building 4, room three, room 4302 Patentee before: TUKE (TIANJIN) PHARMACEUTICAL TECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: 550025 Guizhou Province in the New District of Guizhou security comprehensive security zone Patentee after: Guizhou Gui'an precision Medicine Co.,Ltd. Address before: 550025 Guizhou Province in the New District of Guizhou security comprehensive security zone Patentee before: ACADEMY OF PRECISION MEDICINE, GUIAN, GUIZHOU Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160120 |